Seres Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the Series Therapeutics Second Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question again, press the star 1. I would now like to turn the conference over to Dr. Carlo Tanzi, Head of Investor Relations. Please go ahead.

Thank you and good morning. Our press release for the company's second quarter 2023 financial results and a business update became available at 7 a.m. Eastern Time this morning and can be found in the Investors & News section of the company's website. I'd like to remind you that we will be making forward-looking statements, including The commercial success of VALS, the timing and results of clinical studies, the ability for microbiome therapeutics to modulate the microbiome and treat or prevent infection, our ability to achieve sales targets and the receipt of future milestones and debt tranches, and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the risk factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so. On today's call, with prepared remarks, I'm joined by Eric Schaaf, series president and CEO, Dr. Lisa Von Mulkey, chief medical officer, Dr. Terry Young, chief commercial and strategy officer, and David Arkowitz, chief financial officer. In addition, Dr. Matthew Henn, chief scientific officer, will also be available to answer your questions. With that, I'll pass the call to Eric.

Thank you, Carlo, and good morning, everyone.